New NIH Award

(Chicago, Illinois) — January 5, 2025
ExoMira Medicine is pleased to announce that scientific co-founders Dr. Deyu Fang and Dr. Huiping Liu of Northwestern University have been awarded a new Multi-Principal Investigator (Multi-PI) R01 research grant from the National Institutes of Health (NIH). The grant, titled “Develop a novel therapy with immuno- and onco-targeting dual efficacies to treat triple-negative breast cancer,” will fund research from January 2025 through December 2029.

ExoMira is honored to serve as the industry partner and sub-awardee on this grant, which aims to advance the development of therapeutics that synergistically combine immunomodulatory and oncogenic pathway inhibition to target one of the most aggressive and treatment-resistant forms of breast cancer. The award further validates ExoMira’s translational science model and its ongoing focus on first-in-class, pancancer therapeutics such as MIRA-1.

This NIH-funded collaboration strengthens the bridge between academic innovation and therapeutic development and exemplifies the critical role of industry-academic partnerships in addressing high-need oncology indications.